Pharmaceutical Executive
Pharmaceutical Executive-12-01-2022
Volume: 42
Issue: 12
Pharmaceutical Executive-11-01-2022
Volume: 42
Issue: 11
Pharmaceutical Executive-10-01-2022 APEX Awards Program
Pharmaceutical Executive-10-01-2022
Volume: 42
Issue: 10
Pharmaceutical Executive-09-01-2022
Volume: 42
Issue: 9
Pharmaceutical Executive-08-01-2022
Volume: 42
Issue: 8
Pharmaceutical Executive-07-01-2022
Volume: 42
Issue: 7
Pharmaceutical Executive-06-01-2022
Volume: 42
Issue: 6
Pharmaceutical Executive-05-01-2022
Volume: 42
Issue: 5
Pharmaceutical Executive-04-01-2022
Volume: 42
Issue: 4
Pharmaceutical Executive-03-01-2022
Volume: 42
Issue: 3
Pharmaceutical Executive-02-01-2022
Volume: 42
Issue: 2
Pharmaceutical Executive-01-01-2022
Volume: 42
Issue: 1
Pharmaceutical Executive-12-01-2021
Volume: 41
Issue: 12
Pharmaceutical Executive-11-01-2021
Volume: 41
Issue: 11
Pharmaceutical Executive-10-01-2021
Volume: 41
Issue: 10
Pharmaceutical Executive-09-01-2021
Volume: 41
Issue: 9
Pharmaceutical Executive-08-01-2021
Volume: 41
Issue: 8
Pharmaceutical Executive-07-01-2021
Volume: 41
Issue: 7
Pharmaceutical Executive-06-01-2021
Volume: 41
Issue: 6
Pharmaceutical Executive-05-01-2021
Volume: 41
Issue: 5
Pharmaceutical Executive-04-01-2021
Volume: 41
Issue: 4
Pharmaceutical Executive-03-01-2021
Volume: 41
Issue: 3
Pharmaceutical Executive-02-01-2021
Volume: 41
Issue: 2
Pharmaceutical Executive-01-01-2021
Volume: 41
Issue: 1
Pharmaceutical Executive-12-01-2020
Volume: 40
Issue: 12
Pharmaceutical Executive-11-01-2020
Volume: 40
Issue: 11
Pharmaceutical Executive-10-01-2020
Volume: 40
Issue: 10
Pharmaceutical Executive-09-01-2020
Volume: 40
Issue: 9
Pharmaceutical Executive-08-01-2020
Volume: 40
Issue: 8
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
5
